Why Big Pharma is betting on telehealth strategies
Published On Sep 6, 2024, 4:52 PM
Big pharmaceutical companies, particularly Eli Lilly and Pfizer, are increasingly adopting direct-to-consumer (DTC) telehealth strategies. Eli Lilly aims to combat unauthorized competitors of its GLP-1 medications by providing telehealth services for conditions like obesity and diabetes through its LillyDirect platform. Meanwhile, Pfizer seeks to leverage its COVID-19 vaccine recognition to boost sales in other areas via its PfizerForAll telehealth service. This new model allows companies to create a loyal customer base by enhancing patient experiences and gaining valuable consumer data, ultimately driving adherence to medications. Although challenges remain, experts believe this approach may reshape the pharmaceutical industry's landscape, particularly regarding prescription distribution and pricing.